Key facts
- TeraCyte’s last known valuation is $9.0M (Apr 2023).
- It has raised $1.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include MedTech Innovator, Stata Capital Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for TeraCyte
- ·The full record, as it builds
Funding rounds
No funding rounds for TeraCyte are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TeraCyte
Developer of computational models designed to predict cellular responses to various stimuli. The company offers analytical capabilities, facilitating the understanding and forecasting of cell reactions to new drugs or perturbations in the medical field, enabling pharmaceutical researchers and medical professionals to make informed decisions regarding drug development and treatment strategies.
- Sector
- Healthcare
- HQ
- Caesarea, Israel
- Founded
- 2019
- Employees
- 20
- Website
- teracyte.ai/
- Ownership
- Privately Held (backing)
TeraCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TeraCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TeraCyte in its N-PORT filings yet. We sweep new filings monthly.